ENTXのチャート
ENTXの企業情報
| symbol | ENTx |
|---|---|
| 会社名 | Entera Bio Ltd （エンテラ・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism osteoporosis and bone healing. エンテラ・バイオはイスラエルのバイオ医薬品企業。有効な治療法が確立されていない疾患のための治療薬の発見、開発および商品化に焦点を当て事業を行う。主に副甲状腺機能低下症および骨粗しょう症の治療薬として経口カプセルの開発を手掛ける。主要製品候補には、副甲状腺ホルモンの治療薬EB612や、骨粗しょう症および癒着不能骨折の治療薬EB613などがある。 Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. |
| 本社所在地 | Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 ISR |
| 代表者氏名 | Gerald M. Lieberman ジェラルド・M・リーバーマン |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | ― |
| 設立年月日 | 40330 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.enterabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/entx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.65700 |
| 終値（lastsale） | 5.85 |
| 時価総額（marketcap） | 66855672 |
| 時価総額 | 時価総額（百万ドル） 60.11296 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 88.47196 |
| 当期純利益 | 当期純利益（百万ドル） -10.02400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Entera Bio Ltd revenues was not reported. Net loss decreased 31% to $2.6M. Lower net loss reflects FV Adjustments of Financial Investments increase from $479K to $2.9M (income) GENERAL AND ADMINISTRATIVE EXPENSES (INC decrease of 70% to $854K (expense) Other financial expenses (income) net increase from $71K (expense) to $23K (income). |
ENTXのテクニカル分析
ENTXのニュース
Entera Bio''s (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript 2022/03/08 16:09:08 Seeking Alpha
Entera Bio GAAP EPS of -$0.47 beats by $0.58, revenue of $0.57M beats by $0.03M 2022/03/08 11:44:08 Seeking Alpha
Entera Bio press release (ENTX): FY GAAP EPS of -$0.47 beats by $0.58.Revenue of $0.57M (+54.1% Y/Y) beats by $0.03M.
Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) 2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review 2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts 2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) 2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review 2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts 2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
Entera Bio (NASDAQ:ENTX) Issues Earnings Results, Beats Estimates By $0.03 EPS 2021/11/12 00:42:42 Transcript Daily
Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.12) by $0.03, Fidelity Earnings reports. Entera Bio had a negative return on equity of 161.80% and a negative net margin of 3,414.71%. Entera Bio stock traded up $0.02 []
Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) 2021/11/21 07:24:42 Transcript Daily
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []
Kodiak Sciences (NASDAQ:KOD) & Entera Bio (NASDAQ:ENTX) Head-To-Head Review 2021/11/18 16:14:42 Dakota Financial News
Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk Kodiak Sciences has a beta of 1.39, indicating that its stock price is []
Entera Bio Ltd. (NASDAQ:ENTX) to Post FY2021 Earnings of ($0.77) Per Share, B. Riley Forecasts 2021/11/16 07:16:41 Dakota Financial News
Entera Bio Ltd. (NASDAQ:ENTX) Stock analysts at B. Riley lifted their FY2021 earnings estimates for shares of Entera Bio in a research note issued to investors on Thursday, November 11th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($0.77) per share for the year, up from their previous []
Entera Bio (NASDAQ:ENTX) Issues Earnings Results, Beats Estimates By $0.03 EPS 2021/11/12 00:42:42 Transcript Daily
Entera Bio (NASDAQ:ENTX) released its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts consensus estimates of ($0.12) by $0.03, Fidelity Earnings reports. Entera Bio had a negative return on equity of 161.80% and a negative net margin of 3,414.71%. Entera Bio stock traded up $0.02 []